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ABSTRACT
Background
Recurrent IVF failures may result from implantation defects of which a thin endometrium is 
often implicated. Studies show that improved endometrial thickness increases the probability 
of successful IVF.
Objectives
To evaluate the effects of transcervical instillation of G-CSF as an adjunct to IVF. The study 
looked at the influence of G-CSF on the endometrium and on the achievement of pregnancy.
Methods
A retrospective cross-sectional study of women attending Bio ART Fertility Centre, who had 
two or more failed IVFs previously.
Results
There were a total of 49 women studied with a mean age of 38.9. Mean number of previous 
IVFs were 3.1. Comparison between those that achieved pregnancy and those that did not 
showed that age was a statistically significant factor (p-value 0.0005). Mean endometrial 
thickness pre and post-GCSF between the groups was not statistically significant (p-values 
>0.05).
Conclusion
With the use of G-CSF we achieved a clinical pregnancy rate of 34.69% and a statistically 
significant overall expansion of endometrial thickness (p-value 0.0029). However we failed 
to show any association between endometrial expansion and pregnancy outcome.
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AMH
ART
fl-HCG
FSH
G-CSF
GnRH
hCG
ICSI
Anti-Mullerian Hormone
A hormone produced by granulosa cells in ovarian follicles.
Assisted Reproductive Technology
All treatments or procedures that include the in vitro handling of both 
oocytes and sperm, or embryo for the purpose of establishing a 
pregnancy.1
Beta unit of Human Chorionic Gonadotropin (see hCG)
Follicle Stimulating Hormone
A hormone produced in and secreted by the pituitary gland, which 
promotes the development of sperm and ova.
Granulocyte Colony Stimulating Factor
A glycoprotein/haematopoetic growth factor, also known as colony- 
stimulating factor 3, which stimulates the production and release of 
granulocytes and stem cells from the bone marrow.
Gonadotropin Releasing Hormone
A peptide hormone produced in the hypothalamus and transported 
through the blood stream to the pituitary gland, where it stimulates the 
synthesis and release of pituitary gonadotrophins.
Human Chorionic Gonadotropin
A hormone that is produced by placental tissue. It maintains the 
secretion of progesterone by the corpus luteum in early pregnancy.
Intracytoplasmic Sperm Injection
A procedure whereby a single spermatozoon is injected into the 
cytoplasm of the oocyte.1
IX
IQR Interquartile range
A measure of variability based on dividing a set of data into quartiles. 
The formula is the third quartile minus the first quartile or looking at 
the data between the 25th and 75th percentile with the 50th percentile 
being the median.
IVF In Vitro Fertilisation
The technique whereby an ovum is fertilised outside of the body. The 
zygote is then incubated in a laboratory until an embryo is formed 
which is then implanted in the uterus.
PRP Platelet-rich Plasma
PCOS Polycystic Ovarian Syndrome
RCT Randomised Control Trial
An intervention study to compare the outcome between two randomly 
allocated groups that are deliberately subjected to different regimes
SART Society for Assisted Reproductive Technology
SD Standard Deviation
A measure of the amount of dispersion or variance of a set of data 
values from the mean or average
x
1. CHAPTER ONE - INTRODUCTION
1.1 GENERAL INTRODUCTION
Approximately 15% of couples will not fall pregnant within the first year of trying. This has 
sparked the emergence of novel therapies to try and assist with achieving pregnancy. The 
causes of infertility are multifactorial and manifold. Broadly they can be broken down into 
four main groups: (i) female factor, (ii) male factor, (iii) both female and male factor and (iv) 
unknown.
In Vitro Fertilisation (“IVF”) is a useful modality to overcome some of these female factors 
in that super-ovulation can be induced with hormonal treatment and the in-vitro produced 
embryo can be placed directly into the uterus thus bypassing the fallopian tubes. For males, 
the semen is analysed and sorted, thus ensuring that only suitable sperm is used. In cases of 
severe male factor infertility where sperm morphology, number and motility are a problem, 
the sperm can be injected directly into the ovum (“ICSI”).
For some infertile woman, pregnancy by standard IVF protocols is still not achieved, even if 
ovulation induction and embryo development is successful. This may be as a result of 
defective implantation. One common reason mentioned in the literature is a thin endometrium 
which can adversely affect receptivity of the endometrium to the transferred embryo and 
hence results in failure of the embryo to implant.
1.2 LITERATURE REVIEW
1.2.1 Assisted Reproductive Technology
The World Health Organisation describes Assisted Reproductive Technology (“ART”) as all 
treatments or procedures that include the in vitro handling of both human oocytes and sperm, 
or embryos, for the purpose of establishing a pregnancy. IVF is an ART procedure most 
commonly used in the management of infertility. To date, millions of babies have been bom 
successfully through the use of assisted reproductive technology (“ART”).2 Not only can 
ART be used for the treatment of infertility but also for enhancing the productivity of food 
animals, the conservation of endangered species,3 and even more recently; limiting the
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transmission of HIV in sero-discordant couples.4 Certain genetic illnesses can also potentially 
be eliminated through the use of ART and pre-implantation genetic testing of embryos.
1.2.2 History of IVF
The first “IVF baby”, Louise Brown was bom in Britain in 1978. However, experiments into 
IVF had begun as early as a century before, in 1878. The ability to fertilise oocytes in vitro 
has enabled major advances in reproductive technology and has expanded our knowledge and 
understanding regarding the process of fertilisation and early embryo development. This 
technology, though expensive and not readily available to all, has afforded many infertile 
couples the chance of pregnancy.
1.2.3 Infertility and causes thereof
Infertility is a common presenting problem in the practice of Obstetrics and Gynaecology 
with approximately one in six couples being affected.5 Most texts defines infertility as the 
failure to achieve pregnancy after a period of 12 months with regular sexual intercourse 
without contraception. There appears to be an increasing prevalence of infertility in recent 
years. The exact reason for this is difficult to determine. It is speculated that the increase 
could be due to the fact that women nowadays are focusing more on their careers and hence 
delaying marriage and childbearing until they are older. It has been demonstrated through the 
evaluation of Follicle Stimulating Hormone (“FSH”) and Anti-Mullerian Hormone (“AMH”) 
levels that advancement in age is associated with reduced ovarian reserve and decreased 
reproductive potential.6
Habits such as smoking and alcohol consumption are on the rise and this can negatively
r  n
affect semen and oocyte quality. ’ Also not to negate environmental factors such as radiation, 
with the increased use of cell phones, and its effect on semen and oocyte quality and
n
number.
According to The Society of Assisted Reproductive Technology (“SART”) database of
o _
2013 , the causative factors and frequency are as follows:
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Table 1.1: Causes of infertility and frequency thereof
Tubal Factor 6% Male Factor 16%
Ovulatory Dysfunction 7% Other Factor 7%
Diminished Ovarian Reserve 18% Unknown Factor 13%
Endometriosis 3% Multiple Female Factor 12%
Uterine Factor 1% Female and Male Factor 17%
1.2.4 Granulocyte Colony Stimulating Factor (“G-CSF”) in ART
G-CSF was initially identified as a growth factor for neutrophils. It is encoded for by a single 
gene located on chromosome 17 ql 1 -22 and is produced mainly by cells of monocyte or 
macrophage origin.9 In recent years, many additional effects of G-CSF on cell mediated 
immunity have been uncovered. It has been suggested that the use of G-CSF may in fact be 
beneficial in the treatment or prevention of immune mediated diseases such as graft-vs-host 
disease, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease and 
diabetes.10
Studies have shown that G-CSF also has an important role to play in human reproduction and 
this has been the basis for further studies which have combined the use of G-CSF and ART. 
G-CSF through its “action on neutrophilic granulocyte proliferation and macrophages of 
decidual cells” has been shown to positively affect implantation. ’ In addition, “G-CSF 
recruits dendritic cells, promotes Th-2 cytokine secretion, activates T regulatory cells and 
stimulates various proangiogenic effects”.10,11 A study by Scarpellini F et al. has shown 
success with the use of G-CSF in the treatment of patients with recurrent and unexplained 
pregnancy losses.13
G-CSF has been found to be synthesized de novo in the female reproductive tract and hence it 
is hypothesized to have some influence on the growth and development of the embryo.11 
Spandorfer et al. conducted a study to determine whether G-CSF produced by autologous 
endometrial co-culture was associated with an improved outcome. The study looked at 53 
patients with a history of multiple IVF failures. It involved analyzing the culture media which
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contained endometrial cells either exposed or unexposed to human embryos. Their results 
showed that the level of G-CSF was not influenced by embryo exposure. Interestingly 
however, it showed that the level of G-CSF present did affect pregnancy outcomes, i.e. 
patients that had G-CSF levels > 130pg/ml were more likely to fall pregnant than those that 
had levels < 130pg/ml, and this result was statistically significant (P<0.05).11,14
Ziebe et al. in 2013 published a multicenter, randomized, placebo-controlled, double-blind 
prospective study, to evaluate the effect that G-CSF in embryo culture medium has on 
ongoing implantation rates. They looked at the ongoing implantation rate at 7 weeks 
gestation, then at 12 weeks and lastly at actual birth rate. It was concluded by their study that 
the addition of G-CSF to culture media increased the survival of the transferred embryos to 
week 12 and actual live birth rate.11,15
1.2.5 The effect of endometrial thickness on fertility
There are various factors to consider when determining the possibility of successful 
pregnancy with IVF therapy. These include the age of the patient, the number of oocytes 
aspirated, the quality of the embryos cultured and also the receptivity of the endometrium 
onto which the embryos are to implant. Problems with any of these factors can result in failed 
IVF therapy, and the presence of more than one of these factors will further decrease the 
likelihood of achieving pregnancy.
The measurement of endometrial thickness is an indirect measure of endometrial receptivity 
and is measured in the midsagittal plane by transvaginal ultrasound.16,17 There is no evidence 
to state what is considered an exact ideal endometrial thickness, but it is thought to be
between 7mm and 14mm. There are studies that show that an endometrial thickness of
16 18< 7mm or > 14mm correlates negatively with implantation rates. ’
Al-Ghamdi et al. conducted a retrospective cohort study looking at the correlation of 
endometrial thickness on the day of hCG administration and pregnancy outcomes. It was a 
large study analysing 2464 cycles of IVF. The result of the study showed a positive linear 
relationship in pregnancy rate from 29.4% in patients with an endometrial thickness < 6mm, 
to 44.4% in patients with an endometrial thickness > 17mm.16
Richter et al. in a retrospective study looking at 1294 IVF cycles, investigated the 
relationship between endometrial thickness and implantation. They found a significant
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correlation between clinical pregnancy and live birth rates with increasing endometrial 
thickness.19 Importantly, they noted that this correlation was independent of the patients’ age 
or the quality of the embryo transferred. Both of these are confounding factors and can also 
affect implantation success.
1.2.6 Therapies to improve endometrial thickness and/or receptivity
There are various therapies being employed to try and induce endometrial receptivity and 
thus improve implantation and pregnancy rates with IVF. These therapies are either 
hormonal/chemical or mechanical and will be discussed further.
Hormonal/ chemical
Sher et al. showed that vaginal sildenafil improved endometrial development in 70% of their 
patients studied, which resulted in higher implantation and ongoing pregnancy rates. 
Another study by Takasaki et al. showed that in addition to sildenafil, vitamin E and 1- 
arginine also has the potential to increase endometrial thickness by increasing uterine radial 
artery blood flow.21 Sildenafil more commonly known by its popular trade name “Viagra” is 
a phosphodiesterase 5 (PDE5) inhibitor and a potent vasodilator.
Exogenously administered oestrogen and progesterone in a variety of regimens can be used to 
induce endometrial receptivity.22 Chen et al. showed that extended oestrogen administration
'y i
followed by frozen-thawed IVF programs is beneficial for women with thin endometrium.
Qublan et al. in a randomised placebo-controlled trial of 120 women with thin endometrium 
< 7mm, showed that women who received GnRH agonist on the day of oocyte retrieval, on 
the day of embryo transfer and again 3 days later, had significantly higher oestrogen and 
progesterone levels, a thicker endometrium, and higher implantation and pregnancy rates 
compared with the placebo group.24'25
A study in Leeds, UK, by Acharya S et al. looked at using combined pentoxifylline and 
tocopherol (Vitamin E) in women with a thin endometrium (< 6mm) who were undergoing 
assisted reproductive therapies. They found that its use was associated with improved 
endometrial growth.
5
Mechanical
‘Endometrial scratch’ has become a colloquial term used to describe a procedure whereby 
multiple endometrial biopsies are taken.
It is hypothesised that this procedure may enhance endometrial receptivity and thus 
implantation in the following ways:
“local injury to the proliferative phase endometrium might induce the decidualisation 
of the endometrium and increase implantation rates;’’27
“local injury to the endometrium might provoke wound healing, involving a massive 
secretion of different cytokines and growth factors... which are beneficial for embryo 
implantation;”
Controlled ovarian hyperstimulation during IVF therapy might result in the 
endometrium showing histological advancement which can negatively affect embryo 
implantation.27 “Local injury to the endometrium during the controlled ovarian 
hyperstimulation cycle might result in a ‘lag’ in the development of the endometrium, 
so that the development of the endometrium is more equivalent with the development
• . 77of the embryo and also increase its receptivity.”
Studies by Barash et al.14 and also by Zhou et a l21 are in keeping with the above theory. 
Important to note however, that this procedure must be done in the luteal phase of the cycle 
preceding the IVF treatment.24
A recent study published only last year in the International Journal of Clinical and 
Experimental medicine, evaluated the effectiveness of autologous platelet-rich plasma 
(“PRP’) on endometrial growth and pregnancy outcomes. It was a small study group, 
comprised of 5 infertile women with thin endometrium (< 7mm). The conclusion from the 
study was that PRP is able to promote endometrial growth and improve pregnancy 
outcomes.28 However, owing to the small sample size; further study into this experimental 
treatment is yet required.
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1.2.7 Studies on the use of G-CSF with IVF therapy
The pioneer researcher who initially started experimenting with the use of G-CSF in the field 
of fertility was a specialist from the United States by the name of Nobert Gleicher.
His first publication was in 2011. It was a prospective cohort study of only 4 patients.29 All 4 
of the patients had a thin endometrium (< 7mm). His intervention was the intrauterine 
perfusion of G-CSF. The main outcome measure was endometrial thickness on the day of 
embryo transfer with pregnancy as a second outcome. From the study he reported successful 
expansion of the endometrium to minimal thickness (> 7mm) within approximately 48 hours 
from G-CSF infusion. All 4 patients achieved pregnancy but one required termination as it 
was a cornual ectopic.29
Gleicher then went on to head yet another study, this time with 21 patients. The study design 
was the same as his previous study with the same intervention and the same outcome 
measures. Again his study showed a significant change in endometrial thickness (P <0.001). 
They had an ongoing clinical pregnancy rate of 19.1% with the exclusion of one pregnancy 
which was an ectopic.30
Soon after, a RCT of 141 patients was published by Barad DH et al. Interestingly these 
patients were not selected based on their endometrial thickness or history of previous IVF 
treatment failures. The control group received G-CSF and the placebo group received saline. 
The conclusion of this study was that G-CSF does not affect endometrial thickness, 
implantation rates or clinical pregnancy rates compared to saline.31
Eftekhar M et al. later published an intervention study specifically evaluating the effect of 
transvaginal perfusion of G-CSF on improving endometrial thickness and pregnancy 
outcomes. The study group consisted of 68 patients with thin endometrium (< 7mm) 
undergoing assisted reproduction treatment in a frozen embryo transfer program. Thirty-four 
of these patients received G-CSF. The study failed to show that G-CSF improved endometrial 
thickness but showed that its use was associated with improved chemical and clinical 
pregnancy rates. The result however was not found to be statistically significant. The 
authors “think that exogenous G-CSF infusion as chemical stimuli and intrauterine infusion 
as mechanical stimuli may induce secretion of endogenous cytokines and activated the 
endocrine-paracrine pathways that probably contributed to embryo implantation and 
pregnancy.”32
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Kunicki et al.' s study conducted in Poland also looked at the effect of G-CSF on women 
undergoing IVF who have treatment-resistant thin endometrium (< 7mm). This study was 
conducted somewhat differently. It involved 37 patients, all of whom received G-CSF. The 
researchers then divided the patients into two groups based on whether they conceived or not. 
The clinical pregnancy rate was 18.9%. They then looked at the change in endometrial 
thickness experienced by the two groups and found significant endometrial expansion in both 
groups.33
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1.3 RESEARCH QUESTION
In a certain number of infertile women, pregnancy is not achieved even with multiple 
attempts of IVF. As shown from the studies described above there is conflicting research as 
to the effect of G-CSF on the endometrial lining as well as its influence on pregnancy 
outcomes. Some studies have shown that G-CSF improves endometrial thickness and 
pregnancy rates while others have shown it to have no effect on the endometrial thickness but 
is associated with improved clinical pregnancy rates; and still others have shown it to have no 
effect on endometrial thickness or pregnancy rates when compared to saline. Where 
improved pregnancy rates have been shown, it is also not clear as to the exact mechanism 
whereby this improvement is attributed. Literature suggests that G-CSF may exert its positive 
effect via a chemical, hormonal or a mechanical effect or via an as yet uncertain alternative 
mechanism enhancing implantation.
BioART used G-CSF in women with failed IVF from January 2015. This study evaluated the 
outcomes in these women in terms of pregnancy rates and endometrial expansion.
1.4 AIM OF THIS STUDY
To describe the outcomes in women who had transcervical intrauterine instillation of G-CSF 
as an adjunctive treatment to IVF in the management of infertility. These women all had at 
least two previous failed attempts at IVF. All of them underwent IVF treatment between 
January 2015 to August 2015 at BioART fertility centre.
1.5 OBJECTIVES
The objectives of the study were twofold:
1. To describe the effect of transvaginal intrauterine instillation of G-CSF, in adjunct to 
IVF treatment on pregnancy rates;
2. To describe the effect of transvaginal instillation of G-CSF on endometrial thickness.
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2. CHAPTER TWO -  METHODS AND MATERIALS
2.1 METHODS
2.1.1 Study design
This was a retrospective cross-sectional study analysing the data of women who had 
undergone treatment involving G-CSF instillation and IVF.
2.1.2 Setting
BioART Fertility Centre is situated at the Brenthurst Clinic in Johannesburg. It is run by two 
obstetrician and gynaecologists who are also specialists in reproductive medicine. The 
complete team is comprised of a clinical manager, nursing staff, psychologist, laboratory 
technicians and embryologist. All treatments were done on site. It is a busy practice that 
attracts patients from all over Johannesburg, South Africa and also throughout the African 
continent including countries like Malawi, Nigeria, Cameroon, Gabon and the Democratic 
Republic of Congo. They do an average of 800 IVF cycles a year.
2.1.3 Study population
This was a specific subgroup of women who had previously had at least two failed attempts 
at pregnancy with IVF either at BioART or other fertility centres. There were no other 
specific inclusion or exclusion criteria. Women who attend BioART Fertility Centre are 
either on medical aid or are cash paying clients, but presumably have sufficient resources to 
afford fertility treatment which can be quite expensive. IVF is not freely available in the state 
setting and is often not covered for by most medical aids.
At BioART, on the first visit the patient or couple is seen by one of the specialists and then 
also by the psychologist. A complete history is taken, an examination is performed. Any 
relevant investigations for example an ultrasound is performed. Further investigations like a 
hysterosalpinogram if necessary are then scheduled. A semen analysis is booked to exclude 
male factor infertility. Should any surgery be indicated for example a diagnostic/operative 
laparoscopy, this will also be discussed and scheduled. Once all the relevant investigations 
have been done and the cause of infertility is established plans for assisted reproduction are 
made. Should IVF be warranted this will be discussed and the protocol to be used will be 
decided upon and date for commencement of treatment will be scheduled.
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2.1.4 Sampling
A consecutive sample of eligible, consenting women, taken from the date of the introduction 
of this new treatment adjunct at BioART i.e. 21/01/2015 until the 31/08/2015.
Technique o f transvaginal G-CSF instillation
The patient was placed in lithotomy position. The vulva and vagina were then cleansed with a 
disinfectant solution (Savlon - Cetrimide 3.0% w/v and Chlorhexidine Gluconate 0.3% w/v). 
A Cusco speculum was inserted into the vagina to visualize the cervix. The cervix was then 
also swabbed with disinfectant solution. A Tomcat catheter was inserted through the cervical 
canal into the mid-cavity of the uterus; the exact position was calculated from the most recent 
ultrasound scan done for endometrial monitoring. If a Tomcat catheter was not available, a 
semi-rigid embryo transfer catheter was used. One ampoule of G-CSF [NeupogenR 
(filgrastim)], at room temperature, was drawn up into a 2 ml syringe and attached to the 
catheter. The G-CSF was injected, no flush was used. The catheter was then withdrawn and 
the speculum removed. Patient was left to lie supine for a further 10-15 minutes thereafter.
2.1.5 Sample size
Sample size was determined by the number of women who had undergone IVF treatment 
with adjunctive transvaginal instillation of G-CSF in the above mentioned time frame. These 
women also satisfied the specific inclusion criteria.
Our study sample consisted of a total of 49 women. Other studies using G-CSF had between 
4 and 141 subjects.29'33
2.2 EXPLANATORY VARIABLES
Age, parity, gravidity, previous obstetric history, cause of infertility, previous fertility 
treatments, IVF protocol used, fluid in the endometrial cavity, donor oocytes, embryo grading 
and cryopreservation.
Four different IVF protocols were used in this study, namely;
1. Long protocol (midluteal GnRHa downregulation protocol),
2. Step up protocol (agonist antagonist protocol),
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3. Frozen embryo transfer protocol (natural cycle/ hormonally manipulated cycle),
4. Oral ovulation induction protocol (clomiphene/ clomiphene and letrozole 
combination)
The protocols have been attached hereto and marked “Annexure A”. The protocol chosen for 
use was patient specific.
Fluid in the endometrial cavity was observed by transvaginal ultrasound pre G-CSF 
instillation. The volume was not measured and its presence or absence was merely noted.
Embryos were graded on the third day of culture according to the appearance of the embryo 
under the microscope using Veeck’s day 3 scoring criteria. (Attached hereto and marked 
“Annexure B”.)
There are two main methods of cryopreservation, namely the slow cooling and the rapid 
cooling method. The laboratory at BioART fertility centre uses the rapid cooling method also 
known as the “Vitrification” method. The protocol used for embryo vitrification as well as for 
thawing has been attached hereto and marked “Annexure C”.
2.3 OUTCOME VARIABLES
The primary outcome measure was the confirmation of pregnancy. The pregnancy result was 
initially determined ‘biochemically’ by serum 13-HCG processed at Lancet laboratory at the 
Brenthurst Clinic on day 10 post embryo transfer. Should the result have been negative and 
no bleeding per vagina had occurred, the test was repeated on day 12. If the result was 
positive the patient was then seen after two weeks for an ultrasound to confirm an ongoing 
pregnancy (clinical pregnancy). The secondary outcome measure was the measurement of 
endometrial thickness post G-CSF instillation compared with pre G-CSF instillation.
The Lancet laboratory does both qualitative and quantitative testing of serum 13-HCG. The 
received blood sample in a SST (serum-separating tube) is spun down using a centrifuge at a 
speed of 4000 RPM (revolutions per minute). For qualitative testing, the “TOYO(R” hCG 
pregnancy cassette test is used. Serum is drawn into a dropper and 3 drops (120pl) are placed 
into the sample well of the cassette. Results are read within 10 minutes. One coloured line 
visible indicates a negative result and two coloured lines visible indicate a positive result.
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This test has a sensitivity of 99.4% and a specificity of 99.9%. The positive predictive value 
is 99.9% and the negative predictive value is 98.4%. Quantitative testing is done using the 
“VIDAS®” hCG test. This is an automated test and uses enzyme linked fluorescent assay 
technique in order to quantify measurement of hCG. With this test the smallest concentration 
of hCG detectable with a 95% probability is < 2mIU/ml.
Endometrial thickness is determined by transvaginal ultrasound and is measured as the 
maximum anterior to posterior distance visualized when looking at the uterus in a mid- 
sagittal view. Endometrium pre G-CSF was measured on the day of “triggering”, and post G- 
CSF on the day of embryo transfer. Transvaginal G-CSF instillation was done 2 - 4  days pre­
embryo transfer. Triggering is the final step in oocyte maturation and is usually achieved by 
administering either a GnRH agonist like Leuprorelin or hCG.
2.4 DATA COLLECTION
Data was collected retrospectively. All women who had undergone ART treatment with 
transvaginal G-CSF instillation were recorded. Data was extracted from patient files which 
also contained a G-CSF specific information sheet. (Attached hereto and marked “Annexure 
D”.) Data was entered into an Excel spreadsheet. (Attached hereto and marked “Annexure 
E” )
2.5 DATA ANALYSIS
The data was exported to Stata 14.1® (StataCorp,4905 Lakeway Drive,College Station, Texas 
77845 USA) for data analysis. Categorical variables were described using frequencies and 
percentages, and continuous variables were described using means (with SD) and medians 
(with IQR). Comparisons were made using the Chi-squared or Fishers exact test. Continuous 
variables were compared using the Student T test or the Wilcoxon Mann Whitney test. A 
difference was noted to be statistically significant when the p- value was < 0.05.
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2.6 ETHICS
Approval to conduct this study was sought and granted unconditionally from the University 
of the Witwatersrand’s Human Research and Ethics Committee (Clearance certificate no: 
Ml 50961). (Attached hereto and marked “Annexure F” ) Consent for use of data by Bio ART 
was obtained in writing (Attached hereto and marked “Annexure G”.) Consent was also 
implied as Dr Cassim was a supervisor, and both practitioners will be involved in the 
manuscript for publication. No identifying data was captured. All file numbers were given a 
study number and this was kept separately in a locked cupboard within the BioART practice.
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3. CHAPTER THREE -  RESULTS
In this chapter I will begin with a description of the study population, the demographics and 
the fertility history. I will then look specifically at the endometrial thickness, pre and post G- 
CSF instillation as well as data specific to the IVF cycle, that being, the type of oocytes used, 
the number and quality of the embryos transferred, the IVF protocol used and whether there 
was fluid noted in the endometrium or not. I will then go on to describe the pregnancy 
outcomes. Lastly I will compare those that achieved pregnancy and those that did not, and 
will compare the results of the two groups according to demographics, fertility history, the 
cause of infertility and cycle specific factors.
3.1 Demographics
There were a total number of 103 women who underwent ART therapy with G-CSF in the 
period between 21/01/2015 -  31/08/2015. Of these the medical notes of 49 of these women 
were reviewed. These women had at least 2 or more failed attempts at pregnancy with IVF 
previously and were treated with G-CSF instillation in addition to their IVF protocol. Women 
that were excluded had either less than 2 previous failed IVFs or had G-CSF instillation with 
another form of ART other than IVF, for example, ovulation induction and intrauterine 
insemination.
The ages of women ranged between 28 and 51. The mean age was 38.90 (SD ± 6.11) and the 
median age 38 (IQR 34 - 42). The distribution of women’s ages is illustrated in Figure 3.1 
below.
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Figure 3.1: Age distribution of study population
The mean parity of the women was 0.35 (SD ± 0.60) and the median was 0 (Range 0 - 2).
The mean gravidity of the sample was 1.04 (SD ± 1.09) and the median was 1 (Range 0 - 4). 
The mean paternal age was 42.70 (SD ± 6.96) and the median was 41.5 (Range 29 - 61). In 3 
of the cases the paternal age was not known. The reason being that of theses 3 cases, 2 used 
donor sperm and the third was a new file and had missing information as the old file had been 
lost.
The smoking history of the women was not well documented in the files, with only the 
history of 4 patients being recorded (all of whom were confirmed to be non-smokers) and the 
history of the other 45 unknown.
3.2 Fertility History
The number of previous IVF treatments ranged between 2 and 10, as shown in Table 3.1 
below. The mean number of previous IVF treatments was 3.14 (SD ± 1.77) and the median 
was 2 (IQR 2 -  4).
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Table 3.1: Number of previous IVF cycles
Number of previous IVFs Frequency Percentage (%)
2 25 51.02
3 11 22.45
4 6 12.24
5 3 6.12
6 1 2.04
8 2 4.08
10 1 2.04
3.3 Endometrial thickness
The endometrial thickness pre G-CSF treatment ranged between 1.1mm and 12mm. The 
mean thickness was 7.53mm (SD ± 2.69) and the median was 7.5mm (IQR 6.1 - 9.8). A 
graphical description of the distribution of endometrial thickness pre G-CSF is depicted in 
Figure 3.2 below.
Figure 3.2: Endometrial thickness pre G-CSF in the study population
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The endometrial thickness post G-CSF as illustrated in Figure 3.3 below, ranged between 
4.8mm and 14mm. The mean thickness was 9.11mm (SD ±2.12) and the median was 8.8mm 
(IQR7.5-11).
Figure 3.3: Endometrial thickness post G-CSF in the study population
Comparison of the mean endometrial thickness pre- and post- G-CSF using the paired t-test 
yielded a p-value <0.001, implying that the difference noted is statistically significant. This 
difference is illustrated by the box plot shown in Figure 3.4 below.
Figure 3.4: Box plot showing comparison of endometrial thickness pre and post G-CSF 
in the study population
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The box plot in Figure 3.5 below shows graphically the comparison of the mean endometrial 
thickness pre- and post- G-CSF for specific women with a “thin endometrium” (pre G-CSF < 
7 mm).This yielded a p-value = 0.0004, showing statistically significant expansion of the 
endometrium post G-CSF instillation.
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Figure 3.5: Box plot showing comparison of endometrial thickness pre and post G-CSF 
in the women with “thin endometrium” (pre G-CSF < 7mm)
3.4 Cycle specific data
Eleven of the 49 women used donor oocytes. One women used both own and donor oocytes 
as shown in Table 3.2 below.
Table 3.2: Types of oocytes used
Oocyte type (donor/own) Frequency Percentage (%)
Both 1 2.04
Donor 10 20.41
Own 38 77.55
Embryos transferred were then either fresh embryos or thawed from previously 
cryopreserved embryos. Two women had both fresh and thawed embryos transferred. Of
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these 2 women, one used embryos produced from her own oocytes (fresh) in addition to 
embryos produced from donor oocytes which had been cryopreserved. The second women 
used own fresh embryos from the current IVF cycle and in addition used thawed embryos 
that had been cryopreserved from a previous IVF cycle. Table 3.3 below shows the types of 
embryos transferred.
Table 3.3: Types of embryos transferred
Embryos transferred 
(Fresh/thawed)
Frequency Percentage (%)
Fresh and thawed 2 4.08
Thawed 27 55.10
Fresh 20 40.82
The mean number of fresh embryos transferred was 2.83 (SD ± 1.14) and the median number 
was 3 (IQR 2 - 4).
The mean number of frozen embryos transferred was 3.77 (SD ± 1.31) and the median 
number was 3.5 (IQR 3 - 5).
For the purpose of analysis we divided the embryos into good, intermediate and poor quality. 
Good embryos were either grade lor 2. Intermediate embryos were grade 3 and poor quality 
embryos were grade 4 and 5.
The majority (47) had at least 1 good quality embryo as shown in Table 3.4 below.
Table 3.4: Embryo quality
Embryo quality Frequency Percentage (%)
Good 47 95.92
Intermediate 1 2.04
Poor 1 2.04
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3.5 Fluid in the endometrial cavity
Of the 49 women 3 of them had fluid noted in the endometrial cavity on ultrasound pre G- 
CSF instillation.
3.6 IVF protocol used
There were a total of 4 different protocols used. The most commonly used protocols were the 
long protocol and the frozen embryo transfer protocol as shown in Table 3.5 below.
Table 3.5: IVF protocol used
IVF protocol used Frequency Percentage (%)
Frozen embryo transfer 
protocol
25 51.02
Long protocol 18 36.73
Step up protocol 4 8.16
Oral ovulation induction 
protocol
2 4.08
3.7 Pregnancy outcomes
As shown in Table 3.6 below, 17 women had a positive clinical pregnancy and 32 failed to 
fall pregnant.
Table 3.6: Pregnancy outcome
Pregnancy outcome Frequency Percentage (%)
Positive 17 34.69
Negative 32 65.31
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Table 3.7 below shows that younger women were more likely to fall pregnant and this was 
statistically significant. There was no statistically significant difference in the other 
demographic factors. Similarly there was no statistically significant difference observed with 
regards to the causes of infertility or cycle specific factors as shown in Table 3.8 and 3.9 
respectively.
3.7.1 Pregnancy outcomes related to demographics and fertility history
Table 3.7: Pregnancy outcomes related to demographics and fertility history
Pregnancy 
N=17 (34.69%)
No pregnancy 
N=32 (65.31%)
p-value
Demographics
Age -  mean (SD) 34.94 (±  1.15) 41 (±5.76) <0.001
Age -  median IQR) 34 (31 -37 ) 40 (36.5 -  46) 0.001
Age<35 10(62.5%) 6 (37.5%) 0.004
Age<37 13(45.52%) 10 (43.48%) 0.003
Parity - mean (SD) 0.44 (±0.16) 0.31 (±0.10) 0.495
Gravidity - mean 
(SD)
1.06 (±.023) 1.03 (±0.21) 0.925
Paternal age - mean 
(SD)
41.29 ( ± 2.15) 43.31 (±1.14) 0.362
Fertility history
Number of previous 
IVF’s -mean (SD)
3.18 (±0.40) 3.13 (±0.33) 0.922
Comparison of the mean age using the two sample t-test yielded a p-value of <0.001, 
affirming that the mean age difference between those women that achieved pregnancy and 
those that did not, was statistically significant. This comparison is illustrated graphically in 
Figure below.
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Figure 3.6: Box plot showing comparison of age between women who achieved 
pregnancy verses those that did not
3.7.2 Pregnancy outcomes related to cause of infertility
Table 3.8 displays the causes of infertility and the pregnancy outcome. There was however no 
statistically significant association noted for any particular cause of infertility and the 
attainment of pregnancy. Of the 49 women, 3 of them had pelvic structural abnormalities 
which were contributory to their infertility. More specifically, one of these women had severe 
pelvic adhesions, the other had asherman’s syndrome and the third woman had a uterine 
septal defect. A reduced ovarian reserve was determined by the measurement of AMH levels. 
For the women said to have chronic endometritis, this diagnosis was made histologically 
following a diagnostic dilatation and curettage. One these two women, one was found to have 
TB endometritis.
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Table 3.8: Pregnancy outcomes related to cause of infertility
Pregnancy 
N=17 (34.69%)
No pregnancy 
N=32 (65.31%)
p-value
Female causes of infertility
PCOS
n=7 (14.29%)
1 (14.29%) 6(85.71%) 0.397
Adenomyosis 
n=5 (10.2%)
1 (20%) 4 (80%) 0.646
Endometriosis 
n=l 1 (22.45%)
3 (27.27%) 8 (72.73%) 0.725
Fibroids 
n=6 (12.24%)
1 (16.67%) 5 (83.33%) 0.650
Pelvic structural 
n=3 (6.12%)
0 (0%) 3 (100%) 0.542
Tubal
n=14 (28.7%)
6 (42.86%) 8 (5.14%) 0.516
Ovulatory 
dysfunction 
n=4 (8.16%)
0 (0%) 4(100%) 0.284
Reduced ovarian 
reserve
n=19 (38.78%)
6(31.58%) 13 (68.42%) 0.767
Chronic endometritis 
n=2 (4.08%)
0 (0%) 2(100%) 0.537
Male causes of inferti lity
T eratozoospermia 
n=l 0(20.41%)
3 (30%) 7 (70%) 1.000
Azoospermia 
n=2 (4.08%)
1 (50%) 1 (50%) 1.000
Oligospermia 
n=4 (8.16%)
0 (0%) 4 (100%) 0.284
Decreased motility 
n=2 (4.08%)
0 (0%) 2(100%) 0.537
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3.7.3 Pregnancy outcome related to cycle specific data
Table 3.9: Pregnancy outcome related to cycle specific data
Pregnancy No pregnancy p-value
All women n=17 (34.69%) n=32 (65.31%)
Number of Embryos 
transferred 
(Fresh/thawed) -  
mean (SD)
3.82 (±  1.29) 3.13 (±3.13) 0.081
ET pre-GCSF -  
mean (SD)
7.6 ( ± 0.72) 7.49 ( ± 0.46) 0.891
ET post-GCSF -  
mean (SD)
9.14 (±0.57) 9.10 (±0.44) 0.954
n=13 (34.21%) n=25 (65.79%)
ET expansion (Post 
G-CSF -  Pre G-CSF)
1.76 (±2.61) 1.70 (±  1.58) 0.933
Women with ET 
pre-GCSF < 7 mm
n=6 (31.58%) n=13 (68.42%)
ET pre-GCSF -  
mean (SD)
5.48 ( ± 2.20) 5.68 (±  1.20) 0.147
ET post-GCSF -  
mean (SD)
8.03 (±  1.54) 8.05 (±2.11) <0.001
ET expansion (Post 
G-CSF -  Pre G-CSF)
2.55 (±3.64) 2.36 (±  1.87) 0.882
Table 3.10 below compares pregnancy outcomes and the various IVF protocols used. 
Table 3.10: Pregnancy outcome related to protocol used
Pregnancy [N, (%)] No pregnancy [N, (%)]
Frozen embryo transfer protocol 6 (35.29%) 12 (37.5%)
Long protocol 1 (6.88%) 3 (9.38%)
Step up protocol 9 (52.94%) 16 (50.00%)
Oral ovulation induction protocol 1 (6.88%) 1 (3.13%)
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3.7.4 Univariate analysis
Table 3.11: Univariate analysis of factors associated with a clinical pregnancy
Odds ratio 95% Confidence interval
Age 0.80 0.69 - 0.93
Parity 1.41 0.53-3.75
Gravidity 1.03 0.59-1.79
Paternal age 0.96 0.89-1.05
Post thickness ET 1.01 0.73 - 1.39
IVF cycle 1.02 0.73-1.42
Use of donor eggs 2.45 0.59-10.2
Number of embryos transferred 1.50 0.92 -  2.45
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4. CHAPTER FOUR -  DISCUSSION AND CONCLUSION
This is the first study in South Africa describing the pregnancy rates with the use of G-CSF 
as an adjunct to IVF in the treatment of infertility. Our study was unique in that all woman 
included had failed two more IVF cycles previously and not all of them had a thin 
endometrium. This study adds to the growing pool of research looking at the various effects 
of G-CSF and its use in reproductive health.
4.1 Pregnancy outcomes
IVF treatment was successful in 17 of the 49 women resulting in a pregnancy rate of 34.69%. 
These women had a positive pregnancy test followed by ultrasound confirmation.
29 30 32Most studies to date have shown good pregnancy rates with the use of G-CSF. ' ’
In our study, the only statistically significant difference noted between those that achieved 
pregnancy and those that did not, was age (p-value <0.001). The average age of those who 
fell pregnant was 35 and 41 for those who did not.
The pregnancy rate achieved at BioART in the year 2014 was 45.68%.Stratifying this data 
according to age the pregnancy rates in those less than 35 years, between 35-37, 38-40, 41- 
42, and more than 42 years; were 52.00%, 42.85%, 32.89%, 33.33% and 46.42% 
respectively. With the use of G-CSF, we now found pregnancy rates in the same age 
categories of 62.29%, 44.44%, 12.50%, 33.33% and 8.33% respectively. We are unable to 
make direct comparisons with regards to these results as the 2014 rates are the overall rates at 
BioART for the year not taking into account the woman’s previous fertility treatments. In our 
study the women in whom G-CSF was used were a particular subset in that they already had 
failed 2 or more previous IVF treatments.
Table 4.1 below is a comparison according to age of the pregnancy rates achieved at BioART 
in 2014 compared with the United States national 2014 rates as displayed in the summary 
report on the SART website.
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Table 4.1: Comparison of pregnancy outcomes according to age
Age BioART 2014 SART National summary report 201454
<35 52.00 31.90
35-37 42.85 26.50
38-40 32.89 18.30
41-42 33.33 10.50
>42 46.42 3.60
The pregnancy rates with G-CSF adjunctive therapy are higher than the rate previously 
obtained at BioART and is approximately double the US national rates in the age groups < 35 
years and 35-37 years. However the true difference can only be determined using a RCT.
4.2 Endometrial thickness
Some studies have shown G-CSF to have an effect on endometrial expansion whilst others 
have shown it to have no effect on the endometrium. As part of the second objective in this 
study, we set out to describe the effect that G-CSF had on our study population. A thin 
endometrium was however not a criteria for the study or for the use of G-CSF.
In our study sample, the mean endometrial thickness before G-CSF instillation was 7.35 mm 
and post G-CSF instillation, it was 9.11 mm. The overall expansion in endometrial thickness 
post G-CSF was found to be statistical significant. (P-value < 0.001)
However a comparison of the mean endometrial thickness pre G-CSF and post G-CSF 
between those that fell pregnant and those that failed to fall pregnant showed no statistically 
significant difference between the 2 groups. (P-value 0.891 and 0.954 respectively)
It has been shown previously that endometrial thickness is an important independent factor in 
predicting the outcome of pregnancy with IVF. A recent systematic review and meta-analysis 
of 22 studies assessed the clinical significance of endometrial thickness and IVF outcome. 
260 of the 10 724 reported cases had a thin endometrium <7 mm. The probability of a clinical 
pregnancy for patients with a thin endometrium was significantly lower when compared to
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patients with endometrial thickness > 7 mm [23.3% vs 48.1%, OR=0.42 (95% Cl 0.27- 
0.67)].45
In our study, of the 49 women, 22 had a pre G-CSF endometrial thickness of < 7 mm. By 
looking specifically at these 22 women, comparisons regarding endometrial expansion post 
G-CSF were made. From these 22 women, 3 had to be excluded from analysis as the post G- 
CSF measurement was not recorded in the medical notes. Comparison of the means of pre 
and post G-CSF endometrial thickness showed statistical significance endometrial expansion. 
(P-value <0.001).
4.3 Study demographics and fertility history
4.3.1 Age, parity and gravidity
The median age of our study population was 38 years. The median gravidity was 1 and the 
median parity was 0.
We found that younger women were more likely to fall pregnant and that the rate decreased 
by 20% with every additional year of age.
Our study like others has shown that age is an independent predictor of IVF success.34'37 A 
retrospective and comparative study by Kdous M et al, of 500 women who underwent an 
ICSI cycle, found significantly lower pregnancy rates in older women (> 38 years).34 Tsaffir 
A et al, also in a retrospective study looked specifically at patients aged 40 years and older at 
the start of IVF treatment. The study had a sample size of 381 women and a total number of 
1217 IVF cycles. This study showed that success rates declined with each year after age 40. 
Pregnancy and delivery rates were 13.9 and 9.1% respectively at age 40 and 2.8 and 0.7% 
respectively at age 45.35
Dhillon RK et al, in their study to determine which pretreatment patient variables have an 
effect on live birth rates following assisted reproduction, found that increasing age (>36 
years) was associated with reduced chances of IVF/ICSI success.36 The reduction in IVF 
success with advancing age may be attributed to reduced ovarian reserve evidenced by 
declining AMH levels. However, a retrospective study by Revelli et al, looking at the 
outcome of 448 IVF cycles in 361 women with low AMH levels (<0.5 ng/ml) found that
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these women still had reasonable chances of achieving pregnancy, but that their prognosis 
was significantly affected by chronological age.37
Our study showed no statistically significant difference when comparing means for parity and 
gravidity between the 2 groups. (P-value 0.5 and 0.93 respectively)
This finding is in keeping with the study by Tsafrir et al mentioned above, which stated that 
prior pregnancy did not influence success of IVF treatment. Rabinson J et al, in their study 
evaluating gravidity on the results of IVF also found that it has no influence on the likelihood 
of achieving pregnancy through IVF.
However, a large analysis of 174 909 ART procedures taken from the German IVF registry 
looked at the impact of reproductive history on IVF and ICSI outcomes. They found that a 
former successful ART procedure resulting in a live birth or a miscarriage was an important
in
prognostic indicator of ART success (p-value <0.0001).
4.3.2 Paternal age
The median paternal age in our study was found to be 41.5 years. Studies have shown that 
paternal age does have an effect on reproductive outcomes. By comparing the mean paternal 
age between our 2 groups we did not find any association between paternal age and 
pregnancy. (P-value 0.37)
A study by Gromoll J et al, which aimed to evaluate the effect that paternal age has on the 
integrity of germinal cells, showed that sperm integrity is affected on both a genetic and 
epigenetic level by age.40 Sharma et al, in their extensive literature review demonstrated 
negative effects on sperm quality and testicular function with increasing paternal age 
affecting reproductive outcomes and IVF/ICSI success.41
Another study by Ghuman et al, looked at the effect that the age of the sperm donor has on 
the outcomes of IVF. Their results did not show any significant effect with advancing age. 
However a limitation of their study was that a sperm donor would seemingly have good 
semen indices and are thus not representative of the general population. Also, none of the 
donors were > 45 years of age.42
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4.3.3 Smoking history
In our sample population only 4 patients were confirmed non-smokers. In the other 45 
patients, the majority, this history was unknown. We also did not know the smoking history 
of the partner. Owing to the fact that our study is retrospective, this is an expected limitation. 
It is thus difficult to draw any conclusions regarding the effect of smoking and the pregnancy 
outcomes observed in our study.
From the literature, it has been shown that smoking is associated with a reduction in 
reproductive potential for both male and females. A review article by Fims et al, looking at 
the effect of various lifestyle factors on IVF outcomes found that male smoking was 
associated with an increased risk of pregnancy loss, and female smoking had an adverse 
effect on ovarian reserve.43
4.3.4 Number o f previous IVF cycles
It is difficult to determine the effect that previous failed IVF cycles may have on one’s 
chances of success with further IVF therapy. There are models to predict IVF success pre- 
first IVF cycle and even after one IVF cycle, but having failed more than one cycle this 
becomes difficult. One may assume that the pathology may be so severe that future attempts 
are also likely to fail, but on the other hand the chance of a success may be higher having 
seen what has not worked previously and where to adjust with subsequent therapies and 
protocols.
The mean number of previous IVF treatments in our sample was 3.14. Our study did not 
reveal any association between the number of previous IVF cycles and the pregnancy 
outcome. (P-value 0.922)
Van Loendersloot et al, attempted to develop a model to predict the chance of pregnancy with 
subsequent IVF cycles, taking into account 13 other variables which could also affect 
pregnancy outcome. The calculated probability in their model ranged between 0.01-0.56. 
They noted that a diagnosis of diminished ovarian reserve, endometriosis and a greater 
number of failed IVF cycles were associated with reduced chance of pregnancy.44
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4.4 Cycle specific data
4.4.1 Fresh vs frozen embryos
There is still much uncertainty surrounding the debate on whether fresh embryo transfer vs 
cryopreserved/thawed embryo transfer is superior or vice versa. In our study, we found no 
association between the type of embryo used and the pregnancy outcome. (P-value = 1)
Other studies have shown that specifically in cases with PCOS, where there is an increased 
risk of pregnancy complications, owing to superovulation, and where abnormal implantation 
and placentation has been described; elective cryopreservation and thawed embryo transfer in 
a subsequent cycle is advocated.46 A cohort study by Roque M et al, compared IVF outcomes 
between fresh embryo and frozen-thawed (“freeze-all policy”) transfer. Fresh embryo transfer 
was only performed in cases with progesterone levels <1.5ng/ml at the time of ovulation 
triggering. The study concluded that outcomes were significantly better in the group using the 
freeze-all policy compared with the group using the fresh embryo transfer.47
4.4.2 Donor oocytes vs own oocytes used
Same as with donor sperm, one would assume that the quality of donor oocytes would be 
good. Patients who choose to use donor oocytes either have severely diminished ovarian 
reserve that they are unable to produce enough oocytes or the quality of their own oocytes is 
not adequate.
Our study showed that there was an increased likelihood of pregnancy when using donor 
oocytes. (OR 2.45, 95% Cl 0.59 - 10.2), but we failed to show any statistically significant 
difference between using either type of oocyte and pregnancy outcome. (P-value = 0.27)
4.4.3 Number o f embryos transferred
In our study the average number of embryos transferred was 3.37 (SD ± 1.33) and ranged 
between 1 and 7. We did not show any statistically significant association between the 
number of embryos transferred and pregnancy outcome. (P-value 0.081)
By increasing the number of embryos transferred in an IVF cycle, one hopes to increase the 
chance of successful pregnancy. Coughlan et al, in their review article on recurrent 
implantation failure states that the probability of a single embryo to implant is approximately 
30%, hence the probability of it failing to implant is approximately 70%. Following the
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transfer of 2 embryos this probability is 49% (0.702 = 0.49). Similarly, the transfer of 3,4,5 or 
6 embryos will reduce the probability of all embryos failing to implant to 34%, 24%, 17% 
and 12% respectively.24 However, the transfer of multiple embryos has its downfall, with the 
increased risk of multiple pregnancies. Women with multiple pregnancies are at higher risk of 
pregnancy related complications and preterm delivery with its associated perinatal problems.
Recently there has been a move towards advocating of single embryo transfers especially for 
women over the age of 35as these women are even more at risk of developing pregnancy 
related complications. To date, studies looking at well selected single embryo transfers show 
promising results in terms of pregnancy outcome as well as reduction of multiple pregnancy 
rates.48’49
4.4.4 Embryo Grade
Embryos are graded so that they may be differentiated in terms of quality. It goes without 
saying that good quality embryos would fare better compared to poorer quality embryos 
when it comes to reproductive success. The probability of failed implantation with a poor 
quality embryo is much higher than that with a good quality embryo. It has been proposed 
that in this case, transferring a greater number of embryos will reduce the probability of all 
embryos failing to implant.24
47 of the 49 patients had at least one good quality embryo (grade 1 or 2). Of the other 2 
patients, 1 had only one grade 3 embryo and the other had three grade 5 embryos. Both these 
patients did not fall pregnant.
As the majority of patients in both groups had good quality embryos, further analysis for 
comparison between the two groups was not done.
4.4.5 Fluid in the cavity
The presence of fluid in the endometrial cavity is thought to affect the outcome of ART by 
negatively affecting implantation rates and is often a reason for cycle cancellation.
Endometrial cavity fluid, > 3.5 mm in anterior-posterior diameter, when associated with tubal 
factor infertility rather than other entities is specifically noted to impair ART outcomes.50'51
Of the 49 patients in our study, only 3 were noted to have fluid in the endometrial cavity.
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Of these 3 patients, only 1 achieved clinical pregnancy. Interestingly, however it was the 
patient with tubal factor infertility that conceived. Owing to the small number of cases, we 
are unable to draw any conclusion on the use of G-CSF and fluid in the endometrial cavity 
and hence no further analysis was done. Additional study in this regard is required.
In the original case report by N.Gleicher et al, of the 4 patients described, one of them was 
noted to have fluid in the endometrial cavity. This patient had the fluid aspirated immediately 
prior to G-CSF instillation and good endometrial expansion was noted thereafter with no 
fluid re-accumulation, and successful implantation and ongoing pregnancy.
A literature search on Pubmed has yielded no further reports on the use of G-CSF for the 
treatment of fluid in the endometrial cavity.
4.4.6 IVF protocol used
The protocol used was patient specific, based on the individual pathology at hand and also on 
experience from previous IVF failures in that patient. Comparison using Fischer’s exact test 
yielded a P value =1 implying that there was no statistically significant association between 
the protocol used and the pregnancy outcome.
4.4.7 Relation to cause o f infertility
Our study showed similar frequency of the different causes of infertility as other studies. 
Adenomyosis, tubal factors, unexplained infertility and ovarian problems have been shown to 
be associated with reduced success for women undergoing infertility treatments. ’ ’
We did not show any statistically significant difference in pregnancy outcome for any of the 
causes of infertility. (P-values > 0.05)
34
4.5 STRENGTHS AND LIMITATIONS
The strengths of the study are:
1) There were only two practitioners involved in this study both of which are enthusiasts 
and specialists in the field of infertility. The overall technique of G-CSF instillation is 
as described above in chapter 2 and was the same for both these practitioners.
2) With regard to the measurement of endometrial thickness between pre and post 
G-CSF instillation, both researchers had their own patients, thus observer bias should 
be negligible.
There were important limitations of this study that need to be mentioned:
1) The measure of pregnancy outcome was based on the result of the pregnancy test i.e. 
either positive or negative as described above. If the pregnancy test was positive, this 
was followed by ultrasound confirmation of an intrauterine gestational sac and later 
by the presence of a fetus with fetal cardiac activity noted. The overall success of the 
treatment however can only be determined by looking at the live birth rate. 
Unfortunately, at BioART, patients are only followed up until 10 weeks of gestation, 
thereafter they continue their antenatal follow up at their chosen / regular obstetrician. 
Information regarding live births was not available at the time of data analysis.
2) This was a retrospective cross sectional study, so some information was missing. 
Some data was not recorded in the files, like smoking history, paternal age and 
endometrial thickness. One file had been lost and a new file had been opened but 
some of the demographic data was then unknown. My impression was that the 
medical notes in most cases were woman rather than couple based unless there was a 
specific male factor for the cause of infertility identified.
3) Our study did not take into account additional variables such as BMI, ethnicity and 
duration of infertility which are known to affect outcomes of IVF treatment.34'36'55
4) We did not set out to determine the difference between women who became pregnant 
and those that did not. Even where differences between the 2 groups had been 
observed this was not shown to be statistically significant as this study was not 
sufficiently powered to determine such differences
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4.6 CONCLUSION
In this study the pregnancy rate was 34.69%. Only a RCT will be able to answer whether this 
rate is indeed superior in women who have had previous failed IVF procedures. Whilst we 
showed an increase in endometrial thickness we were unable to show any statistically 
significant association between endometrial expansion and pregnancy outcome. Again this 
study was underpowered to determine this.
We were unable to show any benefit regarding the use of G-CSF in relation to any particular 
cause of infertility and clinically patients will have to be individualised.
The use of G-CSF and fluid in the endometrial cavity is important to note, however, owing to 
the small number of cases, we are unable to draw any conclusions from our study. Further 
study in this area is needed before the use of G-CSF for the treatment of fluid in the 
endometrial cavity can be advocated.
There is still much research being conducted on the benefits of G-CSF in reproductive health. 
A randomized control trial published recently looked at the effect of the subcutaneous use of 
G-CSF in women with repeated IVF failures. They also reported statistically significant 
improved implantation rates and clinical pregnancy rates even after adjustments for 
participant’s age, endometrial thickness, good quality oocyte counts, number of transferred 
embryos and AMH levels.56
This study is evidence in favour of other workers in this field who have alluded to the fact 
that G-CSF may have other effects on the achievement of pregnancy other than just by the 
expansion of the endometrium.
The overall effect of the use of G-CSF with ART seems promising.
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Femara PROTOCOL IVF / ICSI
NB Please ensure that you collect your medication well in advance so that there is no 
delay in starting treatment on the correct days.
DAY OF
MENSTRUAL
CYCLE
Instructions Things to remember
1. This is the first day of your menstruation / period.
• The first day of the period is the first day 
of full menstrual flow.
• If bleeding commences after 6pm 
(18h00), the next day will be day 1 of 
your period.
• If a brown discharge or spotting continues 
for more than 2 days, take day 3 as your 
day 1 of your period.
• Call the centre or e-mail the 
sisters to book your day 10 
scan. If this falls over a 
weekend please call on the 
Monday.
2. • Do nothing
3. • Do nothing
4. • Start taking your femara tablets. 
Dosage: 5mg daily (2 tablets a day)
• The Femara tablets should 
be taken at the same time 
every day
5. • Continue with femara tablets
6. • Continue with femara tablets
7. • Continue with femara tablets
8. • Continue with femara tablets • This is the last day of 
taking Femara tablets
9. • Do nothing
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10. • You need to be at the centre at 08h30 for 
your first scan.
• After the scan you will be advised when 
your second scan will be. You will be 
monitored until you are ready for the 
aspiration.
• You will be advised 
continually during this 
procedure.
When you are 
ready for 
aspiration
• You will be advised when the aspiration 
will take place.
• You will be given a trigger injection.
• At this point your husband /partner will 
be given a script for antibiotics 
(Zithromax).
• Abstain from intercourse 
from this point.
Day of 
aspiration 
(retrieval of 
eggs)
• On this day you will be told what time to 
be at the centre.
• Aspirations are usually done in the 
mornings.
• You will need the following:
1. ) sperm sample
2. ) Pay the remainder of the fee
• Do not have anything to eat 
or drink 6 hours before the 
aspiration.
• The aspiration is done 
under conscious sedation 
and you may therefore feel 
drowsy after the procedure. 
Please make arrangements 
for someone to drive you 
home
After aspiration • You may telephone the centre daily after 
1 pm to check on the embryos
• We will contact you and inform you when 
the embryo transfer will take place.
Day of embryo 
transfer
• The patient may eat and drink • Preferably take the day off 
work
• After the embryo transfer 
you may resume back to 
your usual activities but 
avoid strenuous work
• You must however abstain 
from intercourse after the 
embryo transfer.
• If the pregnancy test is 
positive you would have to 
abstain until further 
advised.
After the 
embryo transfer
• You must wait for 12 days, and then do a 
beta quantitative pregnancy test.
• Do not stop any medication 
without first consulting the 
centre.
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OCP + HRT CYCLE (for Irregular Cycles)
NB Please ensure that you collect your medication well in advance so that there is no 
delay in starting treatment on the correct days.
Start with the Oral 
Contraceptive Pill when you 
start bleeding.
If you do not have regular menstrual 
cycles, or haven’t seen your menstrual 
cycle for some time; do a pregnancy 
test and if its negative use Provera for 
5 days and when you start bleeding 
start the Oral Contraceptive Pill when 
your menstrual cycle start.
If you use Femodene start in the 
silver line on the packet.
Count 21 days after you've 
started with the first Oral 
Contraceptive Pill and on the 21 
Pill you start with the Lucrin 
Injections. You must finish the 
packed of Oral Contraceptive 
Pills. If bleeding commences 
prior to completing the packet 
of pills, you may stop the pills.
You will have a period when 
you stop the pills.
Start Lucrin injections.
Dosage: units (S)y 18h00 
daily.
Lucrin is administered subcutaneously 
under the skin
Dayl of cycle You may stop the OCP pill Call to book your day 14 scan
Day 4 of menstrual cycle start
- Estrofem mg daily.
- Meticortin lOmg (2 tablets 
per day after breakfast)
Carry on with the Lucrin
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Day 14
After 7 - 1 0  days of taking 
Estrofem you need to come in 
for a scan to assess the 
endometrial thickness of the 
uterus
You need to be at the centre at 
H for your first scan.
The tablets may be altered 
depending upon your response to 
the medication and further 
ultrasound scans may be performed 
depending on the thickness of the 
uterus lining.
When you are ready for your 
transfer, you stop the Lucrin 
and the next day you start with 
the cyclogest. You do continue 
with the Estrofem tablets.
You need to take at least 5 days of 
prontogest. Then continue 
Cyclogest/Uterogestan thereafter.
The number of embryos / straws 
which are thawed will be at the 
discretion of the embryologist. 
Determining factor being the post 
thaw embryo survival.
Start using the Cyclogest 200mg 
vaginal pessories 8 hourly after the 
5 days of prontogest
Start using the Cyclogest 200mg 
vaginal pessories 8 hourly.
Use the following times as a guide: 
morning -  afternoon -  evening 
06h00 - 14h00 - 22h00
Embryo Transfer Day Embryo transfers usually take place in 
the morning. The embryo transfer is a 
relatively easy procedure, whereby the 
embryos are gently placed into the 
uterus using a very fine catheter (tube).
The procedure feels similar to a 
cervical smear test.
You will be given 2 tablets 
(Dormicum 7.5mg and Buscopan 
lOmg) to take which will make you 
drowsy.
You may have something to eat or 
drink on the morning of embryo 
transfer. Preferably take the day off 
work.
After the embryo transfer you may 
resume back to your usual 
activities but avoid strenuous work 
You must however abstain from 
intercourse after the embryo 
transfer. If the pregnancy test is 
positive you would have to 
abstain until further advised.
The Dormicum 7.5mg and 
Buscopan 1 Omg tablets will make 
you feel drowsy. Please make 
arrangements for someone to drive 
you home.
After the embryo transfer You must wait for 12 days, and then do 
a beta quantitative pregnancy test.
Remember to use the cyclogest 
three times a day and you continue 
with the Estrofem tablets.
Do not stop any medication 
without first consulting the centre.
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STEP Up Protocol- Trigger with Lucrin
NB Please ensure that you collect your medication well in advance so that there is no 
delay in starting treatment on the correct days
Day 1 of menstrual cycle
• The first day of the 
period is the first 
day of full 
menstrual flow. 2
• Ifbleeding
commences after 
6pm (18h00), the 
next day will be 
day 1 of your 
period.
• Call the centre or e-mail 
the Sisters to book your 
day 7 scan. If this falls 
over a weekend please call 
on the Monday.
• If a brown 
discharge or 
spotting continues 
for more than 2 
days, take day 3 as 
your day 1 of your 
period.
Day 2 of menstrual cycle You need to do the following:
start with gonadotrophins 
injections e.g. Gonal F, 
Menonys, fostimon or
Start the hormone injections 
(gonadotrophins injections e. 
Gonal F or Menonys or 
______________)
g-
2
Injections (gonadotrophins 
injections e.g. / Menonys
or fostimon___________
should be administered 
roughly at the same time 
every day -  give or take 
ithin 2 hours
If you need to take 
Meticortin, please start 
today.
J
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Day 3 :
Day 4:
Day 5: increase dose to
Day 6:
Day 7 of menstrual cycle
I
• You need to be at the centre at
_H_____for your first scan.
'After the scan you will be advised 
how many more injections you have 
to take
• We will advise you when to start 
with the antagonist (Cetrotide 
0.25mg daily)
• At this point you make another 
appointment for your second scan. 
You will be monitored until you are 
ready for the aspiration.
When you are ready for 
aspiration
You will be advised when the 
aspiration will take place.
• You will be given a trigger 
injection. Lucrin 35units
• Do not take your 
gonadotrophins injections 
on this day until after the 
scan.
• You will continually be 
advised during this 
procedure.
• Abstain from intercourse 
from this point.
• At this point you will be 
informed when to stop your 
Antagonist (Cetrotide) and 
gonadotrophins injections 
e.g. Gonal F, Menonys or
At this point your husband /partner will be 
given a script for antibiotics (Zithromax) 
and you will be given a script for cyclogest 
(progesterone) vaginal pessaries, or 
alternate progesterone.
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Day of aspiration (retrieval 
of eggs)
•  Take th e  d a y  o f f  w ork
• On this day you will be told what 
time to be at the centre.
• Aspirations are usually done in the 
mornings.
• You will need the following
1) Sperm sample
2) Pay the remainder of the fee
• Do not have anything to eat 
or drink 6 hours before the 
aspiration.
• The aspiration is done 
under conscious sedation 
and you may therefore feel 
drowsy after the procedure. 
Please make arrangements 
for someone to drive you 
home.
The day after the 
aspiration.
. • Start using the Cyclogest 
\ .  /utrogestan vaginal pessories
[/* Use one pessory (200mg) three 
times a day; every 8 hours.
• If you are using prontogest, please 
continue 1 per day.
Use the following times as a guide: 
morning -  afternoon -  evening 
06h00 - 14h00 - 22h00
After aspiration • You may telephone the centre daily 
after 1 pm to check on the embryos
• We will contact you and inform you 
when the embryo transfer will take 
place.
Day of embryo transfer
)
• The patient may eat and drink
--------------^
• Preferably take the day off 
work
• After the embryo transfer 
you may resume back to 
your usual activities but 
avoid strenuous work
• You must however abstain 
from intercourse after the 
embryo transfer.
• If the pregnancy test is 
positive you would have to 
abstain until further 
advised.
After the embryo 
transfer
>
• You must wait for 12 days, and then 
do a beta quantitative pregnancy 
test.
• Remember to use the 
cyclogest/utrogestan three 
times a day.
• Do not stop any medication 
without first consulting the 
centre.
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Long Protocol IVF/ICSI - Gonal F
NB: Please ensure that you collect your medication well in advance so that there is no 
delay in starting treatment on the correct days. Please advise the centre of the date that 
you plan to start the Lucrin injections.
File No:______________
Sisters^/ bioartfertilitv.co.za______________0114845119
Day 21 of cycle i.e.
21 days from the first 
day of menstruation -
• The first day 
of the period 
is the first 
day of full 
menstrual 
flow.
• If bleeding 
commences 
after 6pm 
(18h00), the 
next day will 
be day 1 of 
your period.
• If a brown 
discharge or 
spotting 
continues for 
more than 2 
days, take 
day 3 as your 
day 1 of your 
period.
Start Lucrin injections.
Dosage:__________units @ 18h00 daily.
Please ensure that a 
sperm analysis has 
been done.
Lucrin is administered subcutaneously under 
the skin • DO NOT STOP THE LUCRIN UNLESS 
INSTRUCTED TO 
DO SO.
Gonal F Pens should be 
stored in the fridge (not 
Freezer) until used, then it 
can be stored outside the 
Fridge for 28 days
• You may continue to 
have intercourse 
while on the 
treatment; you will be 
instructed on when to 
abstain.
If you do not see your period within two 
weeks of starting the Lucrin injections
PLEASE CONTACT THE CENTRE.
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Day 1 of next 
menstrual cycle
Day 2 of menstrual 
cycle start with 
Gonal F PEN
Dosage:
1. Turn the dial to 
the prescribed dose.
Carry on with the Lucrin
You need to do the following:
Take blood test. (FSH, LH, E2, 
PROGESTERONE) (If this day falls on a 
Nunday you must still have the bloodtest 
taken, there are laboratories open.)
Start the hormone injections 
(gonadotrophins injections e.g. Gonal F) 
only after you had the blood test done.
2. Remove cap of 
needle, and tighten 
the needle onto the 
Gonal F pen.
3. Inject into the 
tummy pushing the 
medication into the 
tummy.
4. Remove needle, 
and close pen with 
the cap, and store in 
fridge.
• Continue with the Lucrin injections.
Call the centre or e- 
mail the nurses to 
book your day 9 scan. 
If this falls over a 
weekend please call 
on the Monday.
Injections 
(gonadotrophins 
injections e.g. Gonal 
F) should be 
administered roughly 
at the same time 
every day -  give or 
take within 2 hours
Doing both injections 
at 18h00 is also 
acceptable.
If you have to use 
Meticortin, please 
start today.
Gonal F pens 
should be stored in 
the fridge until 
used, then it can be 
stored outside the
fridge for 28 days
Day 9 of menstrual 
cycle
You need to be at the centre at 08h00 for your 
first scan.
After the scan you will be advised how many 
more injections you have to take. At this 
point you make another appointment for your 
second scan. You will be monitored until you 
are ready for the aspiration.
Do not take your 
gonadotrophins 
injections e.g. Gonal 
F on this day until 
after the scan.
You will continually 
be advised during this 
procedure.
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When you are • You will be advised when the aspiration will
ready for aspiration take place.
You will be given a trigger injection.
>At this point your husband /partner will be 
given a script for antibiotics (Zithromax) and 
you will be given a script for cyclogest 
(progesterone) vaginal pessaries, or alternate 
progesterone.
Day of aspiration 
(retrieval of eggs)
On this day you will be told what time to be at 
the centre.
Take th e  d a y  o f f  
w ork
• Aspirations are usually done in the mornings.
You will need the following: 1 .Sperm sample 
2. Pay the remainder of the fee ______
The Day after the 
aspiration.
Start using the Cyclogest vaginal pessories. 
Use one pessory (200mg) three times a day; 
\every 8 hours.
After aspiration You may telephone the centre daily after 1pm 
to check on the embryos. We will contact you 
and inform you when the embryo transfer will 
take place.
Abstain from 
intercourse from this 
point.
At this point you will 
be informed when to 
stop your Agonist 
injections e.g.Lucrin 
and Gonadotrophins 
injections e.g. Gonal 
F
Do not have anything 
to eat or drink 6 hours 
before the aspiration.
The aspiration is done 
under conscious 
sedation and you may 
therefore feel drowsy 
after the procedure. 
Please make 
arrangements for 
someone to drive you 
home.
Use the following 
times as a guide: 
morning -  afternoon 
evening( 06h00 - 
14h00 - 22h00
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Day of embryo 
transfer
• 1 he patient may eat and drink
f t5 *i> r •'T  . s
K e f e X '5 ^
• Preferably take the 
day off work
• After the embryo 
transfer you may 
resume back to your 
usual activities but 
avoid strenuous work. 
You must however 
abstain from 
intercourse after the 
embryo transfer. If 
the pregnancy test is 
positive you would 
have to abstain until 
further advised.
After the embryo 
transfer
• You must wait for 12 days, and then do a beta 
quantitative pregnancy test.
• Remember to use the 
cyclogest three times 
a day.
• Do not stop any 
medication without 
first consulting the 
centre.
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ANNEXURE B
Gradt I (•radc 2 tirade 3 tirade 4 tirade 5
0 © Q & ©
Even
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no
fragmental ton
Even
blastomcfes.
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bUstontercs, 
no
fragmentation
Even or 
uneven size 
Waslomercs* 
moderate 
fragmentation
Unrecognizable
blaslomcrcs,
severe
frugmentairon
Embryo Grading -  Veeck’s scoring criteria
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ANNEXURE C
Embryo Vitrification -  Cook Blastocyst kit
Fill out patient vitrification form
Directions for preparation and use of vitrification kit:
The blastocyst vitrification kit contains solutionl, solution2; solution 3 and solution 4.
Solution 1 - is a cryobase buffer
Solution 2 - contains cryobase buffer with 8% ethelene glycol with 8 % DMSO. Solution 2 is prepared 
by adding 400 ul of solution 4 (DMSO) to 4.6 ml of vitrification solution 2 and mix well
Solution 3 - contains cryobase buffer with Trehalose, 16% ethylene Glycol and 16 % DMSO. Solution 
3 is prepared by adding 1ml of solution 4 (DM SO) to 5.25 ml of vitrification solution 2
Solution 4 - Contains DMSO
Preparation of vitrification dish -  4 well Nunc dish
Take a 4 well Nunc dish. Take 800 ul of Solution 1 and add them into well 1 and 2. Add 2800 ul of 
prepared solution 2 in well. Add 800 ul of solution 3 into well 4.
Equilibrate the three vitrification solutions to 37 °C for 10 mins.
While you let the solutions to equilibrate allocate the canister, goblet and straws for the patient 
according to the availability on the LN storage tanks that are available for cryopreservation by 
looking into the vitrification patient file.
Label the straws with patient surnames; file ID on both the sleeve and straw.
Procedure:
Place the embryos selected for vitrification into well 1 containing solution 1 -  ES and give them a 
wash and transfer them to well 2 containing solution 1. Transfer the embryos from well 2 to well 3 
containing solution 2 for 2 mins. Make a small drop of solution 3 -  VS in the middle of Nunc well dish 
and transfer the embryos into the small drop without making bubbles. Aspirate embryos with the 
pipette from that small drop of solution 3 and load embryos into the hook with minimum quantity of 
media within 1 minute. Now carefully touch the tip of loaded hook with embryos on the cryobath 
block until the drop turns crystal and put them inside the sleeve placed on the LN block.
Now carefully transfer the hooks into the allocated canister and goblet.
Make sure you have made a note of the allocation on the patient forms prior to transfer to LN tanks
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Embryo Thawing
The day before prepare a 4 well Nunc culture dish. The first 2 wells contain universal and the last 2 
wells contain D l-5 culture media, depending on media embryos were cultured in before.
lOmin before thawing, place 4thawing mediums in a 4 well Nunc dish respectively and leave on 
heated stage (30°C) to warm.
Set timer for lm in and remove straw from liquid nitrogen (double check the name) and place on 
paper towel on heated stage. Remove the coloured tip. While holding the straw over the lid of the 
nunc dish, and using clean (cleaned with an alcohol swab) scissors cut the top of straw just under the 
cotton plug. Push the final amount of media out using a syringe. Make sure all the embryos are out 
of the straw.
In the lid of the nunc dish make dilutions of the media from straw media to thawing medial. 
Embryos are gradually moved from drops until in media 1, this is over 5mins.
Dilutions of thawing media 1 to thawing media 2. Embryos are gradually moved from drops until in 
media 2, this is over 5mins.
After embryos are completely in thawing media 2 set heated stage up to 37°C.
Dilutions of thawing media 2 to thawing media 3. Embryos are gradually moved from drops until in 
media 3, this is over lOmins.
Dilutions of thawing media 3 to thawing media 4. Embryos are gradually moved from drops until in 
media 4, as quickly as possible.
After thawing media 4 make 1 dilution drop of media 4 and universal. Then place embryos into 
universal media in culture dish and finally well 4 of culture dish containing Dl-5 culture media.
Place dish containing embryos in incubator for transfer the following day.
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ANNEXURE D
5ASREG ACC ' r T r d
Brenthurst Qinic, Upper Level, West Wing 
4 Parkiane Street, Parwowr., 2183 
Tel - 27 1 1  484 511S • ♦ 27 11 484 5168 • ♦ 27 11 642 0535 
♦  2711642 0593 • ♦ 27 11647 9110 • ♦  27 11647 9111 
Poitsi Addresi P. 0. Box 2590, Houghton 2041 
Fax; ♦  27 11484 5180 
Emergency No: ♦  27 11 3210111 
•vz receptioriijpbioarifertiliry.cc.za
• aziza@bioartferiility.co.za 
www.bioartfertiiity.co.za
GRANULOCYTE - COLONY STIMULATING FACTOR 
(G-CSF) NEUPOGEN
Name :
Age :
File NO. :
Batch NO. 
Treatment Date :
PREV IO U S C Y C L E  H ISTO RY
Previous Number of Biochem Pregnancies
Previous Number of failed IVFs
Cycle Number 1 2 3 4 5 ;
Size of Endometrium
Fluid in the Cavity
Number of Embryos Transferred
Grade of Embryos
.
i
Dr. M.i. Cassim R.gNo 2005-015157/23 Dr. Y.M. Dasoo
BrentHurst Clinic, Upper Level, West Wing 
4 Parkiane Street, Parktown, 2183 
Tel' r 27 1 1  484 5119 • + 27 11 484 5168 • + 27 11 642 0535 
♦  27 11 642 0593 • +27 11 647 9110 * + 27 11 647 9111 
Postai Address P. 0, Box 2590, Houghton 2041 
Fax: ♦  27 11 484 5280 
Emergency No: + 27 11 321 0111 
mail: reception@bioartfertilitv.co za 
• aziza@bioartfertility.co.za 
www.bioartfertility.co.za
CU RREN T C Y C L E  HISTO RY
Number of Embryos Transferred
Grade of Embryos
Transfer Catheter
Ease Level
FHS (Yes / No)
Endometrial Thickness Before
Fluid In Cavity (Yes/No)
Endometrial Thickness Post
Fluid Still Present Post (Yes/No)
Pregnancy (Yes/No)
Repeated IVF/Failure (Yes/No)
How Many ?
Dr. M.l. Cassim Reg Ho:2005/015157/23 
Pr*. No: 016 000 0204 153
Dr. Y.M. Dasoo
ANNEXURE E
S T U D Y
N U M B E R
A G E P A R IT Y P A T E R N A L
A G E
G R A V ID IT Y S M O K IN G C A U S E  O F  
IN F E R T IL IT Y
P R O T O C O L N O . O F  P R E V  
T R E A T M E N T S
E -P R E -G -C S F D O N O R
E G G S
A S P E T T H W D F E T G -I G -II G -III G -IV G -V E -P O S T  G -C S F P R E G  (P O S /N E G )
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
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DATA COLLECTION SHEET
1. Study Number : _______________
2. Age : _______________
3. Parity:_________________
4. Gravidity: _______________
5. Smoker: YES_____ NO______
6. Paternal Age : _________________
7. Cause of infertility : _______________
8. IVF protocol used : _______________
9. Donor eggs : YES_____ NO_____
10. Number of previous treatments : _______________
11. Date of G-CSF instillation : _______________
12. Date of Embryo transfer : ________________
13. Endometrial thickness pre-G-CSF instillation : ______
14. No of oocytes aspirated : _______________
15. No of embryos transferred : _______________
FRESH _____ THAWED _____
16. Fluid in endometrial cavity : YES ______ NO _____
17. Embryo grade : _______________
18. Endometrial thickness post G-CSF : _______________
19. Pregnancy outcome : POSITIVE ______ NEGATIVE
1
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ANNEXURE F
R 14/49 Dr Tasneem Mohamed et al
_
HUMAN RESEARCH ETHICS COMMITTEE (MEDICAL) 
CLEARANCE CERTIFICATE NO. M150961
NAME: Dr Tasneem Mohamed et al
(Principal Investigator)
DEPARTMENT: Obstetrics and Gynaecology
BioART Fertility Centre, Johannesburg
PROJECT TITLE: An Evaluation of the Use of Granulocyte-Colony
Stimulating Factor as an Adjunct to In Vitro Fertilisation 
in Patients who have Previously Failed Attempts at 
Pregnancy with In Vitro Fertilisation
DATE CONSIDERED: 
DECISION: 
CONDITIONS: 
SUPERVISOR:
02/10/2015
Approved unconditionally 
Dr Yasmin Adam
APPROVED BY:
Professor P Cleaton-Jones, Chairperson, HREC (Medical)
DATE OF APPROVAL: 05/10/2015
This clearance certificate is valid for 5 years from date of approval. Extension may be applied for.
DECLARATION OF INVESTIGATORS
To be completed in duplicate and ONE COPY returned to the Secretary in Room 10004, 10th floor, 
Senate House, University.
l/we fully understand the conditions under which I am/we are authorized to carry out the above-mentioned 
research and l/we undertake to ensure compliance with these conditions. Should any departure be 
contemplated, from the research protocol as approved, l/we undertake to resubmit the 
application to the Committee. I agree to submit a yearly progress report
Principal Investigator Signature Date
PLEA SE QUOTE THE PROTOCOL NUMBER IN ALL ENQUIRIES
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ANNEXURE G
• Dr M.I. Cassim
MB Bet (W iO) f.C O .G  (SAJ. 
Mphtl K ep T)) StellmDwdv
Dip B A  (Edinbufllh)
• Dr. Y.M. U»soo 
M BBdi (W iB) f.C .O .G  CSAJ. 
M V  (R*pio Phytiolcgy) 
Sfell«fibcca^
Pi. N o OU 000 020* ’ *3
Fertility Centre
Kog Not 2005A>1S157223
03 September 2015
To whom it may concern
This letter serves to confirm that Dr M.l. Cassim will be the co-supervisor (along with Dr V Adam) for the 
dissertation of Dr Tasneem Mohamed
For her MMed, Dr Mohamed will be evaluating the effects of the use of granulocyte colony stimulating 
factor ( "G CSF") as an adjunct to in vitro fertilization and the achievement of pregnancy.
This study will be done retrospectively and will require her to analyse the data of patients that have 
received treatment with G CSF.
Dr M.l. Cassim and Dr Y. Dasoo have been using this treatment on consenting patients since January this 
year. The literature available thus far has shown varying results regarding this new treatment modality
We, Dr Cassim and Dr Dasoo allow Dr Mohamed access to our patients files so that she may collect the 
necessary data tor analysis and write-up. We do however stress on the anonymity of our patients such 
that all files will be allocated a study number.
Should you have any queries, please do not hesitate to contact us.
Regards
Dr M.l Cassim BioAK 1
Rce No. 2005f01<; 157/23
Dr Y Dasoo
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